Patient characteristics
| Characteristics . | No. of patients . |
|---|---|
| Median age (range), y | 60 (2-91) |
| Sex, M/F | 295/338 |
| Diagnosis | |
| AA | 633 |
| Onset, n (%) | |
| Adult | 616 (97.3) |
| Pediatric | 17 (2.7) |
| Severity at diagnosis, n (%) | |
| NSAA | 385 (60.8) |
| SAA | 191 (30.2) |
| VSAA | 57 (9.0) |
| Treatment | |
| ATG + CsA ± TPO-RA | 230 |
| CsA ± TPO-RA | 205 |
| AS | 22 |
| PSL | 8 |
| HSCT | 3 |
| Others | 2 |
| None | 69 |
| Unknown | 94 |
| Follow-up, median (range), mo | 55 (1-492) |
| Patients with HLA− cells, n (%) | 127 (20.0) |
| Patients with GPI− cells, n (%) | 418 (66.0) |
| Characteristics . | No. of patients . |
|---|---|
| Median age (range), y | 60 (2-91) |
| Sex, M/F | 295/338 |
| Diagnosis | |
| AA | 633 |
| Onset, n (%) | |
| Adult | 616 (97.3) |
| Pediatric | 17 (2.7) |
| Severity at diagnosis, n (%) | |
| NSAA | 385 (60.8) |
| SAA | 191 (30.2) |
| VSAA | 57 (9.0) |
| Treatment | |
| ATG + CsA ± TPO-RA | 230 |
| CsA ± TPO-RA | 205 |
| AS | 22 |
| PSL | 8 |
| HSCT | 3 |
| Others | 2 |
| None | 69 |
| Unknown | 94 |
| Follow-up, median (range), mo | 55 (1-492) |
| Patients with HLA− cells, n (%) | 127 (20.0) |
| Patients with GPI− cells, n (%) | 418 (66.0) |
ATG, antithymocyte globulin; AS, anabolic steroids; CsA, cyclosporine; F, female; HSCT, hematopoietic stem cell transplantation; M, male; NSAA, nonsevere aplastic anemia; PSL, prednisolone; SAA, severe aplastic anemia; TPO-RA, thrombopoietin receptor agonist; VSAA, very severe aplastic anemia.